Company intelligence / Profile preview

Virna Therapeutics

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Virna Therapeutics is a privately held preclinical biotech developing neutralizing monoclonal antibodies and other antiviral modalities against SARS-CoV-2 and other RNA viruses; as of available public information, its candidates had not yet entered human clinical trials and no clinical results have been reported[2][3][4].

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibodySmall moleculeRNA therapyCRISPR-based therapyAntibody
Industry: Biotech

Drug pipeline

1 asset

Virna Therapeutics DUB inhibitor

Preclinical

Partnerships

University of Toronto[3][4]Government of Canada (funding support)[2]Government of Italy (manufacturing and clinical development support)[2]Intonation Research Laboratories (exclusive development and marketing partner for South East Asia)[2]

Beyond the preview

Go deeper on Virna Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Virna Therapeutics.

Explore the full profile